Cargando…

YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells

In heterogeneous head and neck cancer (HNC), subtype-specific treatment regimens are currently missing. An integrated analysis of patient HNC subtypes using single-cell sequencing and proteome profiles reveals an epithelial-mesenchymal transition (EMT) signature within the epithelial cancer-cell pop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Yuchen, Gotz, Carolin, Chincarini, Ginevra, Zhao, Zixuan, Slaney, Clare, Boath, Jarryd, Furic, Luc, Angel, Christopher, Jane, Stephen M., Phillips, Wayne A., Stacker, Steven A., Farah, Camile S., Darido, Charbel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033729/ https://www.ncbi.nlm.nih.gov/pubmed/36949044 http://dx.doi.org/10.1038/s41467-023-37161-0

Ejemplares similares

The Balance between Differentiation and Terminal Differentiation Maintains Oral Epithelial Homeostasis
por: Bai, Yuchen, et al.
Publicado: (2021)

The functional GRHL3-filaggrin axis maintains a tumor differentiation potential and influences drug sensitivity
por: Bai, Yuchen, et al.
Publicado: (2021)

mTOR Signalling in Head and Neck Cancer: Heads Up
por: Tan, Fiona H., et al.
Publicado: (2019)

Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma
por: Goldie, Stephen J., et al.
Publicado: (2019)

YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia
por: Li, Huan, et al.
Publicado: (2023)

Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1
por: Kishikawa, Takahiro, et al.
Publicado: (2016)

YBX1 mediates translation of oncogenic transcripts to control cell competition in AML
por: Perner, Florian, et al.
Publicado: (2021)

Identification and Characterization of Two Novel Oncogenic mTOR Mutations
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2019)

Identification of RNA-binding protein YBX3 as an oncogene in clear cell renal cell carcinoma
por: Wang, Chen, et al.
Publicado: (2023)

Treatments of Squamous Cell Cancer
por: Charbel, Darido
Publicado: (2020)

SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway
por: Xu, Hao, et al.
Publicado: (2018)

Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene
por: Bedekovics, Tibor, et al.
Publicado: (2019)

Squamous Cell Carcinoma—A Summary of Novel Advances in Pathogenesis and Therapies
por: Khan, Imran, et al.
Publicado: (2022)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

mTOR-sensitive translation: Cleared fog reveals more trees
por: Masvidal, Laia, et al.
Publicado: (2017)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Derlin1 functions as an oncogene in cervical cancer via AKT/mTOR signaling pathway
por: Li, Ling, et al.
Publicado: (2019)

Oncogenic Ras is downregulated by ARHI and induces autophagy by Ras/AKT/mTOR pathway in glioblastoma
por: Zhong, Chen, et al.
Publicado: (2019)

Oncogenic mTOR signaling recruits myeloid-derived suppressor cells to promote tumor initiation
por: Welte, Thomas, et al.
Publicado: (2016)

Aurora Kinase A-YBX1 Synergy Fuels Aggressive Oncogenic Phenotypes and Chemoresistance in Castration-Resistant Prostate Cancer
por: Nikhil, Kumar, et al.
Publicado: (2020)

Identification and verification of YBX3 and its regulatory gene HEIH as an oncogenic system: A multidimensional analysis in colon cancer
por: Sun, Yiming, et al.
Publicado: (2022)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
por: Chen, Yonghong, et al.
Publicado: (2023)

Long-Lived Epidermal Cancer-Initiating Cells
por: Youssef, Marina, et al.
Publicado: (2017)

Siccibacter turicensis from Kangaroo Scats: Possible Implication in Cellulose Digestion
por: Dhakal, Sudip, et al.
Publicado: (2020)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

The Pleiotropic Effects of YBX1 on HTLV-1 Transcription
por: Smith, Susan, et al.
Publicado: (2023)

Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression
por: Rad, Ellie, et al.
Publicado: (2018)

Stem Cells behind the Barrier
por: Cangkrama, Michael, et al.
Publicado: (2013)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4hm5c343v987qoc9visug0dlul